Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

AMPA receptor antagonist ER-167288-01 ameliorates neurological status in MS model

Nov. 14, 2001

Novel therapies for dementia and related disorders under study at Elan

Nov. 13, 2001

Synthesis and biological evaluation of new CRF1 receptor antagonists

Nov. 13, 2001

Na+ channel blocker as potential therapy for Parkinson's disease

Nov. 13, 2001

AC-90222 exerts beneficial cognitive and antipsychotic effects in mice

Nov. 13, 2001

NPS receives milestone payment for potential schizophrenia treatment

Nov. 13, 2001

Novel antidementia drug FK-960 more effective than and synergistic with donepezil

Nov. 13, 2001

WAY-812: a potent, long-acting 5-HT1A antagonist identified at Wyeth-Ayerst

Nov. 13, 2001

Lipophilic metal chelator representative of new class of therapies for neurodegenerative disorders

Nov. 13, 2001

Subunit-selective GABA-A receptor agonists in development by Sanofi-Synthelabo

Nov. 12, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026